Free tool
Oncology stocks
We cover 42 companies grouped under the Oncology theme. The median market value in the group is $4.48B. Across the group, the median move over the past trading day is −0.53%. 78% of the 41 with a 200-day average trade above it. Price change over the past year runs from −18.1% to +391.3% across the middle 80 percent of the group, with a median of +58.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
42 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $71.92B | Large cap | +9.21% |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% |
| 4568.T | Daiichi Sankyo Company, Limited | $32.82B | Large cap | −17.94% |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% |
| GE9.DE | Genmab A/S | $20.65B | Large cap | −11.12% |
| IPN.PA | Ipsen S.A. | $15.97B | Large cap | +40.80% |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% |
| SMMT | Summit Therapeutics Inc. | $11.35B | Large cap | −42.63% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +62.83% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +54.43% |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% |
| E2XE34.SA | Exelixis, Inc. | $6.61B | Mid cap | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +196.85% |
| CELC | Celcuity Inc. | $4.65B | Mid cap | +90.31% |
| 000100.KS | Yuhan Corporation | $4.50B | Mid cap | −27.54% |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% |
| 000105.KS | Yuhan Corporation | $3.84B | Mid cap | −32.04% |
| TLX.AX | Telix Pharmaceuticals Limited | $3.82B | Mid cap | +4.88% |
| TLX | Telix Pharmaceuticals Limited | $3.77B | Mid cap | −8.02% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | +135.93% |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% |
| HCM.L | HUTCHMED (China) Limited | $2.16B | Mid cap | −18.08% |
| HCM | HUTCHMED (China) Limited | $2.15B | Mid cap | −17.45% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.